Genedrive plc (AIM: GDR) has highlighted a new case study published by the National Institute for Health and Care Research examining the development, clinical validation and adoption of its Genedrive
ImmuPharma Files International P140 Patent Application
ImmuPharma plc (AIM: IMM) has filed an international Patent Cooperation Treaty application covering its P140 precision medicine approach to autoimmune disease, including identifying and treating patients with the Type M immune
Novacyt Launch of IVDR-Certified Yourgene® Insight DPYD Assay
Novacyt (AIM: NCYT) has launched its IVDR-certified Yourgene® Insight DPYD assay across regulated European markets, expanding the company’s clinical genetics portfolio.
ImmuPharma Appoints Kymos Group to Support Kapiglucagon Development
ImmuPharma plc (AIM: IMM) has appointed Kymos Group as its bioanalytical contract research organisation partner for the development of Kapiglucagon, its proprietary glucagon prodrug for Type 1 diabetes applications.
Genedrive Expands European Adoption with Erasmus MC Implementation
Genedrive PLC (AIM: GDR) has announced that its Genedrive® MT-RNR1 ID Kit has been implemented at Erasmus MC University Medical Center in Rotterdam, expanding the international adoption of its rapid
ImmuPharma appoints Thermo Fisher for drug production
ImmuPharma (AIM: IMM) has appointed Thermo Fisher Scientific to develop and manufacture the finished drug form of Kapiglucagon, its experimental diabetes treatment.
Genedrive Expects FY26 Income to Rise 40% as NHS Adoption Expands
genedrive plc (AIM: GDR) expects to report total income of £1.4 million for the year ended 30 June 2026, up from around £1.0 million in FY25 and in line with
Genedrive technology showcased in Parliament
Genedrive plc (AIM: GDR) has highlighted comments from UK Health Minister Preet Kaur Gill MP, who cited rapid pharmacogenetic testing for antibiotic-induced hearing loss as a practical example of personalised
genedrive partners with Thermo Fisher on NHS testing
genedrive plc (AIM: GDR) has entered into a product development collaboration with Thermo Fisher Scientific to develop a high-throughput CYP2C19 pharmacogenetic test for deployment on Thermo Fisher’s QuantStudio™ 5 Dx
ImmuPharma highlights brain cancer potential for P140
ImmuPharma (AIM: IMM) has highlighted new academic research suggesting its lead drug candidate, P140, may have potential as a treatment for glioblastoma, one of the most aggressive and difficult-to-treat forms
Novacyt S.A. (AIM: NCYT) Launch of Yourgene® Insight DPYD assay
Paris, France and Manchester, UK – 19 May 2026 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces
ImmuPharma advances P140 partnering strategy following £6.5m raise
ImmuPharma PLC (AIM: IMM) said it is actively progressing partnering discussions for its lead autoimmune platform, P140, which remains its primary strategic focus for 2026.